News

Filter

UK’s NICE says “yes” to Genzyme’s MS drug Lemtrada

04-04-2014

In final draft guidance, UK drugs watchdog the National Institute for Health and Care Excellence (NICE)…

BiotechnologyGenzymeLemtradaNeurologicalNorthern EuropeRegulationSanofiUK

NICE recommends Sanofi’s Aubagio as new treatment option for MS

NICE recommends Sanofi’s Aubagio as new treatment option for MS

22-01-2014

In final guidance, UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has…

AubagioBiotechnologyGenzymeNeurologicalNorthern EuropePricingRegulationSanofiUK

Disappointing results for Roche in Phase III schizophrenia studies

Disappointing results for Roche in Phase III schizophrenia studies

21-01-2014

Swiss drug major Roche (ROG: SIX) has revealed disappointing results from two Phase III studies of its…

bitopertinNeurologicalNorthern EuropePharmaceuticalResearchRoche

InteRNA Technologies, UCB and University of Bonn to collaborate on MicroRNAs in neurodegenerative disease

10-01-2014

Dutch pharma company InteRNA Technologies has entered into a collaboration with the Neuroallianz Consortium,…

NeurologicalNorthern EuropePharmaceuticalResearch

Added benefit of Sanofi’s Aubagio not proven, says IQWiG

Added benefit of Sanofi’s Aubagio not proven, says IQWiG

08-01-2014

In yet another negative opinion from the German Institute for Quality and Efficiency in Health Care (IQWiG)…

AubagioGermanyNeurologicalNorthern EuropePharmaceuticalPricingRegulationSanofi

Orion licenses Janssen to develop novel treatment for Alzheimer's disease

Orion licenses Janssen to develop novel treatment for Alzheimer's disease

20-12-2013

Orion Corp has entered into a license agreement with Janssen Pharmaceuticals for the development and…

FinlandJanssenLicensingNeurologicalNorthern EuropeOrion CorpPharmaceutical

Ipsen reports positive Phase III results for Dysport in adult upper limb spasticity

Ipsen reports positive Phase III results for Dysport in adult upper limb spasticity

17-12-2013

French drugmaker Ipsen (Euronext: IPN) has announced positive initial results from a Phase III study…

DysportIpsenNeurologicalNorthern EuropePharmaceuticalResearch

COMPANY SPOTLIGHT

Menarini

Back to top